SkinHealth Systems Lowers Full-Year Revenue Guidance After Q1 Sales Decline
Summary
SkinHealth Systems reported Q1 2026 net sales of $64.9 million, a 6.7% decrease year-over-year, alongside a narrowed GAAP net loss of $6.6 million and adjusted EBITDA of $8.5 million. Crucially, management updated its 2026 guidance, lowering full-year revenue expectations. This news follows yesterday's 8-K filing announcing the termination of the Chief Revenue Officer, which may be related to the company's performance. The revenue decline and reduced outlook are significant negative indicators for the company's growth trajectory, despite efforts to control costs and narrow losses. Traders will be focused on the revised guidance and its implications for future profitability and market positioning.
At the time of this announcement, SKIN was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $117.9M. The 52-week trading range was $0.76 to $2.69. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.